Report Industry Investment Rating No relevant content provided. Core Viewpoints - Market sentiment is shifting towards risk aversion, with attention on the US December CPI data. The inflation narrative is prominent, and future price recovery in China depends on supply - side policies. There are also geopolitical tensions affecting the market, and investors should pay attention to variables in the margin and liquidity markets [2]. - There is a certain divergence in domestic and foreign economic outlooks. Overseas sentiment has declined since October, while China's exports and new orders remain positive. China's November economic data was under pressure, but the December official manufacturing and non - manufacturing PMIs returned to the expansion zone. The US December economic data also showed mixed signals [3]. - In the commodity market, focus on high - certainty sectors such as non - ferrous metals and precious metals. There are potential opportunities for low - valued commodities to catch up. Pay attention to short - term risks in the new energy sector, the situation in Iran and Venezuela in the energy sector, "anti - involution" space in the chemical sector, and weather and disease factors in the agricultural sector [4]. - The strategy for commodities and stock index futures is to buy on dips for stock index futures, precious metals, and non - ferrous metals [5]. Summaries by Related Catalogs Market Analysis - The Central Economic Work Conference in December emphasized boosting consumption and "anti - involution." The 2026 People's Bank of China work conference focused on promoting high - quality economic development and price recovery. Geopolitical tensions between Iran and Venezuela have intensified, and the US Department of Justice's "criminal investigation" of the Fed chairman has added uncertainty. On January 12, the market was strong, with the three major indices rising over 1%, the Shanghai Composite Index achieving 17 consecutive positive days, and AI - related concepts performing well [2]. Economic Data Comparison - China's November foreign trade showed a recovery, with exports increasing by 5.9% and imports by 1.9% year - on - year. November economic data was under pressure, but the December official manufacturing PMI was 50.1 and the non - manufacturing PMI was 50.2, both better than expected. The US December ISM manufacturing index dropped slightly to 47.9, and the non - farm payrolls were lower than expected, but the market remained hot [3]. Commodity Market - In the non - ferrous metals sector, long - term supply constraints remain, and aluminum and nickel are preferred for rotation. In the energy sector, the US plans to "distribute" Venezuelan oil, and Trump has made threats against Iran. In the chemical sector, the "anti - involution" space of methanol and PTA is worthy of attention. In the agricultural sector, weather and short - term pig diseases should be monitored. In the precious metals sector, there are opportunities to buy on dips. On January 12, many commodity futures had significant price increases, and spot gold and silver reached new highs [4]. Strategy - The strategy for commodities and stock index futures is to buy on dips for stock index futures, precious metals, and non - ferrous metals [5]. To - do List - The market showed a strong upward trend on January 12, with the three major indices rising over 1%, the Shanghai Composite Index achieving 17 consecutive positive days, and over 4100 stocks rising. The US December non - farm payrolls were lower than expected, but the unemployment rate decreased. The US January consumer confidence index reached a four - month high. US oil companies are cautious about the Venezuelan investment plan. Trump has made threats against Iran, and the US has launched a criminal investigation into the Fed chairman. Precious metals and some commodity futures had significant price increases [7].

Core Insights - The report highlights significant movements in international and domestic markets, with notable increases in major stock indices across Europe, the US, and Asia, indicating a positive market sentiment [6][11]. - Key developments in government regulations and corporate strategies are outlined, particularly focusing on investment guidelines for government funds and advancements in AI technology [12][13]. International Market Overview - European markets showed mixed results, with Germany's DAX30 index rising by 0.45% to 25,376.43 points, while France's CAC40 index fell by 0.04% to 8,358.76 points [11]. - In the US, the Dow Jones increased by 0.17% to 49,590.2 points, and the Nasdaq rose by 0.26% to 23,733.9 points, reflecting a stable economic environment [11]. - The Asia-Pacific region saw the Hang Seng Index rise by 1.44% to 26,608.48 points, with the Hang Seng Tech Index increasing by 3.1% [11]. Domestic News - New regulations were introduced by four government departments to systematically guide the layout and investment direction of government investment funds, emphasizing support for strategic sectors and innovation [12]. - The Ministry of Industry and Information Technology announced three major actions for the "14th Five-Year Plan," focusing on quantum technology and other cutting-edge fields [12]. - The successful test flight of the Lihong-1 spacecraft marked a milestone in China's commercial space endeavors, achieving a suborbital parachute recovery for the first time [12]. Important Company Developments - Chinese concept stocks experienced a general rise, with the Nasdaq China Golden Dragon Index increasing by 4.26%, and notable gains in companies like Kingsoft Cloud, which rose over 21% [13]. - Nvidia announced a joint investment of $1 billion with Eli Lilly to establish an AI drug development lab, highlighting the growing intersection of AI and pharmaceuticals [13]. - Apple formed a multi-year partnership with Google to leverage AI technologies for future product developments, indicating a strategic shift in its approach to AI [13]. - Significant investments were reported from various companies, including a $3 billion project by Huadian to develop high-density optical integrated circuit boards, expected to generate an annual revenue of 2 billion RMB upon full production [13].

Group 1 - The medical device index ETF (159898) has shown strong performance, with a more than 2% increase in intraday trading, marking four consecutive days of gains, and a total net inflow of 342 million yuan over the past five trading days [1] - Strong Brain Technology, a Chinese brain-computer interface unicorn, has secretly submitted an IPO application in Hong Kong, potentially becoming the first listed company among the "Hangzhou Six Little Dragons," with a fundraising scale expected to reach several hundred million dollars [3] - The brain-computer interface sector is recognized as a significant technological breakthrough, with the national "14th Five-Year Plan" explicitly listing it as a future industry requiring forward-looking layout [3] Group 2 - The commercial pathway for brain-computer interfaces is expanding, with potential applications moving from medical rehabilitation to broader fields such as consumer electronics, smart homes, and industrial safety [3] - The global market for brain-computer interfaces is projected to exceed 10 billion dollars by 2030, with medical applications expected to dominate, and could grow to 145 billion dollars by 2040 [3] - The medical device index ETF (159898) tracks the CSI All-Share Medical Device Index, with 24% of its constituent stocks related to brain-computer interfaces, providing efficient coverage of this cutting-edge sector [4]

Core Viewpoint - The collaboration between Precision Neuroscience and Medtronic aims to integrate brain-machine interface technology with surgical navigation systems to enhance clinical applications in neurosurgery, focusing on real-time visualization of brain structure and function during operations [2][4][14]. Group 1: Collaboration Framework - The partnership centers on the integration of Precision Neuroscience's Layer 7 brain-machine interface (BCI) and Medtronic's StealthStation surgical navigation system [4]. - Layer 7 is a flexible cortical electrode array with a thickness of one-fifth of a human hair, featuring 1024 electrodes for high spatial resolution and designed for minimally invasive implantation [6]. - StealthStation provides real-time 3D imaging for precise anatomical localization during cranial and spinal surgeries, becoming essential in complex brain procedures [8]. Group 2: Clinical Application Expansion - The clinical application of brain-machine interface technology is shifting from chronic control to intraoperative assistance, with Layer 7 initially designed for paralyzed patients now being adapted for rapid functional area identification during surgeries [9][10]. - The integration allows for simultaneous visualization of functional and structural data, aiding in high-risk surgical decisions such as tumor removal while preserving critical brain functions [10]. Group 3: Future Trends in Surgical Data Ecosystem - The collaboration indicates a trend towards a closed-loop surgical data ecosystem, connecting functional signals with real-time surgical systems [11][12]. - This integration could lead to the development of personalized brain function models, potentially creating digital brain maps that track functional status before, during, and after surgery [12]. Group 4: Industry Trends and Implications - The partnership reflects a shift from speculative brain-machine interface concepts to practical clinical applications, emphasizing a step-by-step approach to functional mapping in surgery [13][14]. - The collaboration highlights the importance of integrating high-frequency signal processing and AI analysis to enhance predictive capabilities and decision-making in surgical environments [16].

温馨提示 ： 点击下方图片，查看运营团队最新原创报告（共260页） 说明： 欢迎约稿、刊例合作、行业交流 ， 行业交流记得先加入 "机器人头条"知识星球 ，后添加（ 微信号：lietou100w ）微 信； 若有侵权、改稿请联系编辑运营（微信：li_sir_2020）； 正文： Optimus定型在即， 特斯拉发包中，2026年，首个 T链 定点资讯（名单）来了 ！ 周一（1月12日），在大盘一路上行并持续突破记录下，T链们走势没有延续上周五上行行情，再次进入盘整阶 段。 针对年后T链们 ，在大盘走势大幅上行背景下， 没有 承接去年12月底的主升行情，走势更没有迎来反转的原 因，小编往期文章有提到过" 利好催化不足，缺乏官方"爆点"利好催化，所以仅是核心利好标的行情 "。 从商业航天到自动驾驶再到脑机接口，尤其是商业航天，行情和热度从去年12月延续至今，最热门板块且没有之 一，马年炒"马"的目前逻辑毋庸置疑；唯一的区别，相较于这三者，人形机器人Optimus项目目前还没有阶段性 进展（Optimus V3样机亮相）。 小编去年12月下旬就在星球中提到，对于T链们而言，12月份炒的审厂和"定点"（订单）， 1月 ...

Core Viewpoint - Nvidia and Eli Lilly are investing in AI-driven drug development, establishing a $1 billion lab in San Francisco to accelerate the process [3]. Group 1: Market Performance - Pharmaceutical stocks have seen a rise, with the Shanghai-Hong Kong-Shenzhen medical ETF and biotechnology ETFs increasing by over 4% [1]. - The Hong Kong medical ETF, which covers sectors like CXO, AI healthcare, and innovative drugs, has also shown significant gains [2]. Group 2: Investment Strategies - Huafu Securities emphasizes two short-term focuses: the upcoming JPMorgan conference for identifying outperforming stocks and the beginning of annual report disclosures [4][5]. - The annual strategy includes three main directions for innovative drugs: revenue realization, exceeding expectations in business development, and exploring cutting-edge technology platforms like gene therapy and small nucleic acids [5]. Group 3: Market Trends and Valuation - Haitong Securities notes that the Hong Kong pharmaceutical sector has shown strong performance, with a year-to-date return of 10.77%, leading among various industries [6]. - The average daily trading volume for the Hong Kong healthcare sector has increased to 14.133 billion HKD, reflecting heightened market activity [6]. - The current PE_TTM for the Hong Kong healthcare sector is recorded at 32.29, which is below the 30% percentile of the past three years, indicating relatively low valuation levels [6].

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical sector, indicating a positive outlook compared to the broader market [2][4]. Core Insights - The pharmaceutical sector has shown strong performance, with the SW Pharmaceutical Biotechnology Index rising by 7.81% in the week of January 5-11, significantly outperforming the CSI 300 Index, which increased by 2.79% [2]. - Key drivers of this growth include advancements in brain-computer interfaces, small nucleic acids, and AI healthcare technologies [2]. - The report emphasizes the potential of innovation in overseas markets and hard technology, particularly in AI healthcare and brain-computer interfaces, as major growth areas for the pharmaceutical industry in 2026 [2]. Summary by Sections Industry Overview - The pharmaceutical sector is expected to continue its positive trajectory into 2026, driven by innovation and technological advancements [1]. - The report highlights the importance of the "AI + Health" investment trend, particularly with the launch of the Ant Group's "Afu" app, which focuses on health management [1][2]. Market Performance - The report notes that various sub-sectors, including hospitals, CXO, and medical devices, have experienced significant gains, with increases of 13.92%, 11.15%, and 10.81% respectively [2]. - The Hong Kong market has also seen a rebound in innovative drugs, with the Hang Seng Biotechnology Index rising by 11.06% [2]. Future Outlook - The report identifies three main sources of growth for the pharmaceutical industry: innovation in overseas markets, structural growth under the medical insurance payment framework, and natural growth from government finance and personal demand [2]. - Investment opportunities are expected to arise from the expansion of innovative drugs, hard technology, and the ongoing development of AI healthcare applications [2].

Group 1 - China has developed the capability for independent research and construction of large LNG transport vessels, which are essential for transporting natural gas efficiently, capable of meeting the monthly gas needs of 3.3 million households in a single trip [2] - The newly constructed LNG vessel features a state-of-the-art dual-fuel low-speed propulsion system and a leading liquid cargo containment system that minimizes evaporation losses during long-distance ocean voyages [2] - The dual-fuel propulsion system reduces carbon emissions by over 10 tons per day compared to traditional fuel-driven systems [2] Group 2 - India's recent satellite launch mission failed due to significant deviations in the rocket's trajectory shortly after liftoff, as confirmed by the Indian Space Research Organization [3] - The "Lihong No. 1" spacecraft successfully completed its first suborbital flight test, marking a milestone in China's commercial space endeavors, with a maximum altitude of approximately 120 kilometers [3] - The mission included scientific payloads for microgravity laser additive manufacturing and space radiation experiments, which will be further studied after recovery [3] Group 3 - The Brain-Machine Interaction and Human-Machine Integration Haihe Laboratory is developing a fifth-generation space station brain-machine interaction system, achieving the first human "space brain-machine interface experiment" [3] - The laboratory focuses on non-invasive brain-machine interfaces, promoting technological innovation and industrial application in the aerospace sector [3]

Core Viewpoint - The article discusses the return of Chen Tianqiao, a prominent figure in the Chinese internet industry, who is now focusing on brain-computer interface (BCI) technology and artificial intelligence (AI) through his new ventures, Gestalt and Tanka, emphasizing a long-term vision in these fields [5][6][30]. Group 1: Chen Tianqiao's Return and Investments - Chen Tianqiao announced a $1 billion investment in computational power to support global AI-driven scientific research during a conference in San Francisco [5][23]. - His new company, Gestalt, focuses on non-invasive ultrasound brain-computer interfaces, contrasting with Elon Musk's invasive approach [11][12]. - Tanka, another venture, aims to create a communication platform that integrates AI with human decision-making, redefining organizational management in the AI era [15][16]. Group 2: Brain-Computer Interface Technology - The article highlights the contrasting approaches to BCI technology, with Musk's Neuralink pursuing invasive methods and Gestalt opting for a non-invasive strategy [11][12]. - Gestalt's approach is described as more complex and challenging, aiming for a comprehensive understanding of brain functions without the risks associated with surgical procedures [12][30]. - The potential for Gestalt and Tanka to collaborate could lead to significant advancements in understanding human cognition and emotional regulation [34]. Group 3: Long-term Vision and Challenges - Chen Tianqiao's strategy is characterized by a commitment to long-term research and development in brain science and AI, moving away from traditional business models [30][31]. - The challenges of clinical translation in BCI technology are noted, with timelines often extending over a decade and facing strict ethical and regulatory scrutiny [31][33]. - The article suggests that the intersection of brain science and AI could create new opportunities for innovation and understanding of human behavior [34].

Group 1 - The core viewpoint of the news highlights the significant stock price increase of BGI Genomics, which rose over 5% on January 13, reaching a new high since May 2022, and has accumulated over 36% increase in the first 10 days of 2026 [1] - BGI Genomics was officially included in the CSI A500 index on January 9, 2026, providing clear financial support for the stock price increase and is expected to attract long-term institutional funds, enhancing its brand effect in the capital market [1] - The AI healthcare sector has seen explosive growth in 2026, with OpenAI launching ChatGPT Health and Ant Group's monthly active users surpassing 30 million, significantly raising market expectations for the integration of "AI + life sciences" [1] Group 2 - In 2024, BGI Genomics launched the MGISEQ-2000RS FluoXpert, the first Chinese device integrating AI into the entire process, combining pathological slide imaging and gene sequencing, providing high-precision tools for tumor microenvironment research [2] - The FluoXpert platform's core analysis solution, FluoXpert Vision, introduced an AI Assistant module that integrates the DeepSeek model for intelligent analysis, code writing, and graphical compilation [2] - BGI Genomics is also involved in the brain-computer interface field with its Stereo-seq technology, which offers centimeter-level panoramic views and nanometer-level resolution navigation, participating in national scientific plans and collaborating with top institutions [2] - The global trend in innovative drug and device development is leading to a revaluation of medical data holders, with the "CDO" model showing promising market prospects, and BGI Genomics is expected to benefit from the anticipated growth in data transaction scale and high profit margins [2]